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OBJECTIVES We tested to find out whether pravastatin restores the infarct size (IS)-limiting effect of isch-
emic preconditioning (IP) and if it has any effect on the IP-induced activation of adenosine
producing enzyme ecto-59-nucleotidase which plays a key role in the IP-induced cardiopro-
tection.
BACKGROUND The IS-limiting effect of IP is blunted by hypercholesterolemia. Recently, HMG-CoA
reductase inhibitors are shown to have direct cytoprotective effects.
METHODS Rabbits were fed with a normal or cholesterol (1%) added diet with or without pravastatin
(5 mg/kg/day) treatment. Infarct size was measured after 30 min occlusion and 3 h reper-
fusion of circumflex coronary artery with or without the IP procedure (5 min occlusion and
10 min reperfusion). Additionally, ecto-59-nucleotidase activities of ischemic and nonisch-
emic myocardium were measured immediately after IP procedure.
RESULTS This dose of pravastatin did not normalize the increased level of serum cholesterol. The
IS-limiting effect of preceding IP (IS reduced from 36.7% to 9.6%, p , 0.001) was abolished
by hypercholesterolemia (from 46.1% to 31.3%, p 5 NS) and restored by pravastatin treat-
ment (from 35.2% to 9.4%, p , 0.001). Pravastatin treatment did not affect IS or the effect
of IP under normocholesterolemia. The activation of ecto-59-nucleotidase presented as the ac-
tivity ratio of ischemic to nonischemic myocardium (3.1-fold in normocholesterolemia) was
blunted by hypercholesterolemia (1.8-fold, p , 0.05) and restored by pravastatin treatment
(2.9-fold).
CONCLUSIONS Pravastatin, at the dose serum cholesterol was not normalized, restored the IS-limiting effect
of IP and IP-induced ecto-59-nucleotidase activation, which were both blunted by hyper-
cholesterolemia. The activation of ecto-59-nucleotidase may be worth further investigation as
a possible mechanism for the hypercholesterolemia-induced retardation and pravastatin-
mediated restoration of the cardioprotective effect of IP. (J Am Coll Cardiol 1999;34:
2120–5) © 1999 by the American College of Cardiology
Infarct size (IS) is markedly limited when brief periods of
ischemia precede the sustained ischemia, a phenomenon
known as ischemic preconditioning (IP). This phenomenon
can be extended to the clinical settings because clinical
evidence suggests the acquisition of ischemic tolerance of
the myocardium afforded by antecedent brief periods of
ischemia. In the clinical situation, pathophysiology of myo-
cardial ischemia due to coronary arterial stenosis may be
modified by many risk factors, e.g., hypercholesterolemia
(HC), smoking and hypertension. Recently, we have re-
ported (1) that the IS-limiting effect of IP was blunted by
HC in the rabbit model of myocardial infarction (MI).
Since IP may be a common phenomenon afforded by prein-
farction angina (2) in the patients with acute MI, it is
suggested that HC may increase IS in those preconditioned
hearts. According to a recent report (3), HMG-CoA reduc-
tase inhibitors, which are now commonly used to treat the
patients with HC, have direct cytoprotective action to
endothelial cells. Therefore, it is of great interest to inves-
tigate if pravastatin restores the IS-limiting effect of IP
blunted by HC without normalizing serum cholesterol level.
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Furthermore, since ecto-59-nucleotidase, the enzyme re-
sponsible for adenosine production, may mediate (4) IP, and
its activation correlates (5) with the IS-limiting effect of IP,
we evaluated if HC or pravastatin influences the IP-induced
activation of ecto-59-nucleotidase.
METHODS
Cholesterol feeding and pravastatin treatment. The an-
imal study was approved by the Animal Care and Use
Committee of the Animal Research Institute in Osaka
University. New Zealand White rabbits (n 5 88) eight
weeks old weighing about 1.8 kg (Oriental Co., Japan) were
randomly assigned to the normocholesterolemia (NC)
group (n 5 22), the HC group (n 5 22), the NC with
pravastatin treatment (NCP) group (n 5 22) or the HC
with pravastatin treatment (HCP) group (n 5 22). Hyper-
cholesterolemia was achieved by feeding 1% cholesterol
containing diet (RC4, Oriental Co., Japan) for 16 weeks in
the HC and HCP groups, and the pravastatin treatment
was done by the oral administration of pravastatin (5 mg/
kg/day) in the latter eight weeks in NCP and HCP groups.
After 16 weeks of feeding, serum levels of total cholesterol,
high density lipoprotein (HDL) cholesterol and triglycer-
ides were measured and rabbits were used for the measure-
ment (4) of myocardial IS.
Measurement of myocardial infarct size. Rabbits were
anesthetized with intravenous pentobarbital under respira-
tory control. The heart was exposed with left intercostal
thoracotomy and the left circumflex coronary artery was
ligated for IP (5 min occlusion and 10 min reperfusion) or
MI (30 min occlusion and 3 h reperfusion). The IP proce-
dure was performed in half of the rabbits in each group. The
electrocardiogram, systemic blood pressure and heart rate
were continuously monitored during the procedures. The
oxygen saturation of arterial blood was examined immedi-
ately before coronary occlusion and before reperfusion and
at 3 h after reperfusion. Cardioversion was not done for
ventricular fibrillation. We eliminated the rabbits with
continuous ventricular fibrillation from the data analysis.
The heart was excised after religation of the coronary
artery and the left atrial injection of Evans Blue dye (Wako,
Osaka) to negatively stain the area at risk and then cut into
five to six slices and stained with triphenyl tetrazolium
chloride to determine the infarct area. The infarct area and
the area at risk were determined as the summation of those
areas measured on each picture of the slices with the
assistance of a computer. The IS was defined as the
percentage of infarct area in the area at risk. The weight of
the risk region and of the infarct region was also deter-
mined.
Measurement of the IP-induced activation of myocardial
5*-nucleotidase. Since we have previously reported (4,5)
that the activation of ecto-59-nucleotidase of myocardium is
important for the IS-limiting effect of IP, we measured the
59-nucleotidase activities of myocardium immediately after
IP procedure to clarify the effect of HC and pravastatin on
the 59-nucleotidase and on their activation by IP.
Rabbits (n 5 36) were randomly assigned to the NC
group (n 5 12), the HC group (n 5 12) or the HCP group
(n 5 12). Hypercholesterolemia was achieved by feeding a
0.3% cholesterol containing diet for 10 weeks in the HC
and HCP groups, and the pravastatin treatment was done
by the oral administration of pravastatin (5 mg/kg/day) in
the latter six weeks in the HCP group.
After 10 weeks, serum levels of cholesterol were mea-
sured. Immediately after the IP procedure (5 min occlusion
and 10 min reperfusion of circumflex coronary artery),
myocardium of the ischemic and nonischemic regions was
frozen in liquid nitrogen and stored at 280°C or less until
use for measuring cytosolic and ecto-59-nucleotidase activ-
ities. The activation of 59-nucleotidase by IP was evaluated
by the activity ratio of ischemic to nonischemic myocar-
dium.
Measurement of 5*-nucleotidase activity. The homoge-
nized myocardium was separated into membrane and cyto-
solic fractions as described previously (5). We defined
59-nucleotidase activity in the membrane and cytosolic
fraction as ecto- and cytosolic 59-nucleotidase activity,
respectively. The activity of 59-nucleotidase was assessed by
an enzymatic assay technique (6) and reported as units of
nmol/min/mg protein.
Statistical analysis. All data were presented as mean 6
SD. The changes and differences in the blood pressure,
heart rate and the oxygen saturation of arterial blood were
analyzed by two-way analysis of variance (ANOVA) re-
peated measurements with posthoc analysis of Fisher pro-
tected least significant difference (PLSD). The differences
in the serum levels of total cholesterol, HDL cholesterol and
triglyceride, and the activities of 59-nucleotidase were ana-
lyzed by ANOVA with posthoc analysis of Fisher PLSD.
The relationship between IS and risk region size was
compared among groups with an analysis of covariance
(ANCOVA) with the size of the risk region used as the
Abbreviations and Acronyms
ANCOVA 5 analysis of covariance
ANOVA 5 analysis of variance
HC 5 hypercholesterolemia
HCP 5 hypercholesterolemia with pravastatin
treatment
HDL 5 high density lipoprotein
IP 5 ischemic preconditioning
IS 5 infarct size
MI 5 myocardial infarction
NC 5 normocholesterolemia
NCP 5 normocholesterolemia treated with
pravastatin
PLSD 5 protected least significant difference
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covariant. The correlation between IS and risk region size
was assessed by linear regression analysis using the least
square method. A value of p , 0.05 was considered
significant.
RESULTS
Animals in each group. Excluding some rabbits that died
before the completion of 3 h reperfusion, IS was acquired in
7, 9, 7, 7, 9, 9, 9 and 9 rabbits in NC IP(2), NC IP(1), HC
IP(2), HC IP(1), HCP IP(2), HCP IP(1), NCP IP(2)
and NCP IP(1) groups, respectively. The level of serum
total cholesterol (64.9 6 48.2 mg/dL in the NC group) was
significantly, but similarly, elevated by cholesterol feeding in
the HC (2049.1 6 636.7 mg/dL) and the HCP (1847.9 6
479.2 mg/dL) groups regardless of the pravastatin treatment
and was not significantly changed by pravastatin treatment
alone in the NCP (18.7 6 3.6 mg/dL) group. The level of
serum triglyceride (45 6 39 mg/dL in the NC group) was
also significantly but similarly elevated in the HC (225.3 6
148.3 mg/dL) and the HCP (232.4 6 190.6 mg/dL) groups
regardless of the pravastatin treatment and was not signif-
icantly changed by pravastatin treatment alone in the NCP
(31.8 6 16 mg/dL) group. The level of serum HDL
cholesterol (34.3 6 18.5 mg/dL) was not changed by
cholesterol feeding in the HC (45.6 6 21 mg/dL) or HCP
(45.9 6 40.0 mg/dL) group but was significantly reduced by
pravastatin treatment alone in the NCP group (10.4 6
2.8 mg/dL).
Effects of IP on myocardial infarct size. The interaction
of all factors by two-way ANOVA repeated measurements
was not significant for the data of blood pressure, heart rate
or the oxygen saturation of arterial blood (97% to 98%).
Although no difference was detected among groups, coro-
nary occlusion decreased systolic/diastolic blood pressure
from 115 6 18/74 6 12 mm Hg to 104 6 18/66 6
13 mm Hg and increased heart rate from 275 6 30 to 281 6
31 beats/min. Infarct sizes as the percentage of risk region
are presented in Figure 1. The relationship between the size
of infarct region and the size of risk region is presented in
Figure 2. Infarct size was not different among groups
without IP, meaning that HC or pravastatin did not change
IS. The significant reduction of IS by IP observed in the NC
group was not affected in the NCP group; however, it was
blunted in the HC group and restored in the HCP group.
Effects of HC and pravastatin on the IP-induced activa-
tion of 5*-nucleotidase. The level of serum cholesterol was
also similarly higher in the HC (437 6 310 mg/dL) and
HCP (509 6 171 mg/dL) groups compared with the NC
(26 6 8.5 mg/dL) group in this protocol. Cytosolic and
ecto-59-nucleotidase activities of ischemic and nonischemic
myocardium and their activation by IP in the NC, HC and
HCP groups are presented in Figure 3. Cytosolic and
ecto-59-nucleotidase activities in the nonischemic region
were significantly increased by hypercholesterolemia (HC
and HCP groups), and pravastatin had no influence on
them. However, the activation of ecto-59-nucleotidase by IP
as shown by the activity ratio of ischemic/nonischemic
myocardium was significantly blunted by the HC group and
was restored by pravastatin treatment (HCP group).
DISCUSSION
We performed two independent experiments and revealed,
first, that HC blunts the IS-limiting effect of IP which is
restored by pravastatin treatment although HC or pravasta-
tin does not change IS by itself, and second, that HC blunts
the activation of ecto-59-nucleotidase by IP which is re-
stored by pravastatin treatment. Since the activation of
ecto-59-nucleotidase is essential (4) for the IS-limiting effect
of IP, it is probable that HC blunts the effect of IP via
blunting the activation of ecto-59-nucleotidase and that
pravastatin restores the effect of IP via restoring the activa-
tion of ecto-59-nucleotidase although a causal relationship
has not been proved.
Effect of HC and pravastatin on infarct size. We exam-
ined the effect of HC and of pravastatin on the IS with and
without IP procedure. The results of the study must be
interpreted separately for the direct effect on IS and for the
effect on IP, and there has been no other study so far on the
latter effect. Since the mechanism of IP is not adequately
understood, it may be quite difficult to clarify the mecha-
nism by which HC/pravastatin modify the mechanism of
IP. However, since there are various accompanying factors
that may modify the effect of IP in the patients with
Figure 1. Infarct size as the percentage of risk region. The IS
limiting effect of ischemic preconditioning recognized in NC and
NCP groups is blunted in the HC group but is restored in the
HCP group. Data are presented as means 6 SD. HC 5 hyper-
cholesterolemia group; HCP 5 hypercholesterolemia with prava-
statin treatment group; IP 5 ischemic preconditioning; IS 5
infarct size; NC 5 normocholesterolemia group; NCP 5 normo-
cholesterolemia with pravastatin treatment group. *Significantly
different from NC IP(2) group by ANCOVA (Fig. 2) with size of
the risk region used as the covariant. †Significantly different from
NC IP(1) group by ANCOVA.
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ischemic heart disease, e.g., HC, hypertension, diabetes
mellitus and medical treatments for them, it is very impor-
tant to investigate the influence of those factors and to take
them into consideration when the effect of IP is to be
evaluated in clinical trials. We revealed here for the first
time that one of the factors HC blunts the IS-limiting effect
of IP and was restored by pravastatin treatment without
normalizing the serum cholesterol level, meaning that prav-
astatin exerted its effect, not through the reduction of serum
cholesterol levels but through some other unknown mech-
anism.
Hypercholesterolemia did not change the IS in this study
with rabbits although HC was reported to increase IS partly
by reducing the collateral flow in dogs (7). Although this
difference between dogs and rabbits cannot be explained by
the information available so far, this may partly be due to
the difference in the amount of collateral flow; collateral
circulation is well developed in canine hearts but it is not in
rabbit hearts.
Although chronic treatment with the present dose (5 mg/
kg/day) of pravastatin in HC rabbits did not significantly
change the serum level of total cholesterol in accordance
with the results in the previous reports (8–11), the IS-
limiting effect of IP was completely restored. Since prava-
statin did not decrease IS in NC rabbits, it is likely that
pravastatin restored some factors involved in the mecha-
nisms of IP which were disturbed by HC. These factors
have never been discussed in the previous reports and
further investigations are required to clarify them.
Our hypothesis on the IS-limiting effect of IP and
adenosine. The IS-limiting effect of IP would be influ-
enced by the cardiac interstitial adenosine levels following
the activation of 59-nucleotidase. The important determi-
nant of the cardiac adenosine levels in the preconditioned
myocardium is the extent of the increases in the activity of
59-nucleotidase, which can be revealed by the ratio of the
activity of 59-nucleotidase between the preconditioned and
nonpreconditioned area of the hearts (bottom panel of Fig.
3) judging from our previous investigations. Since the basal
adenosine levels are determined not only by 59-nucleotidase
but also adenosine kinase, adenosine deaminase and the
adenosine uptake capability, even if the basal activity of
59-nucleotidase is high, the interstitial adenosine levels may
not be increased. If the basal cardiac adenosine levels are
comparable in the HC and the HCP groups and 59-
nucleotidase in the HCP group is further activated beyond
the levels of the HC group due to IP procedure, this extent
of increases in 59-nucleotidase may cause the increases in
the adenosine levels which may contribute to the limitation
of IS. Therefore, the difference in 59-nucleotidase activity
before and after ischemia, but not the basal activity of
59-nucleotidase itself, may be important for the determina-
tion of the IS-limiting effect of IP. Although we need to
further investigate whether this hypothesis is correct, we
interpreted the present data based on this hypothesis.
Possible mechanism involved in the restoration of the
IS-limiting effect of IP blunted by HC. No direct action
of HMG-CoA reductase inhibitors to endothelial or myo-
cardial cells has been reported except for one recent report
(3) which revealed their direct effect to upregulate endothe-
lial nitric oxide synthase. In this study, we demonstrated
that the IP-induced activation (4) of ecto-59-nucleotidase of
myocardium (as shown by the activity ratio of ischemic/
nonischemic myocardium) is blunted by HC and is restored
by pravastatin treatment possibly through its direct action
besides reducing serum cholesterol level since the serum
cholesterol level was not reduced in this study. Furthermore,
we demonstrated that ecto-59-nucleotidase activity of the
nonischemic myocardium are increased by HC and are not
affected by the pravastatin treatment, meaning that the
activation of ecto-59-nucleotidase by IP is blunted by HC
regardless of the increased activity of ecto-59-nucleotidase in
the nonischemic region and that pravastatin restored the
activation without changing the increased activity of ecto-
59-nucleotidase. Therefore, HC has influence not only on
the activity of ecto-59-nucleotidase itself but also on the
mechanism of its activation by IP. Since the activation of
ecto-59-nucleotidase by IP negatively correlates with IS (5),
Figure 2. Relationship between the size of infarct region and the
size of risk region. The linear regression line of each group is
presented. In all groups, IS was positively and linearly related to
risk region size. Linear regression equations were as follows: NC
IP(1), y 5 0.26x 2 0.12; NC IP(2), y 5 0.58x 2 0.20; HC
IP(1), y 5 0.08x 1 0.17; HC IP(2), y 5 0.52x 2 0.05; HCP
IP(1), y 5 0.09x; HCP IP(2), y 5 0.52x 2 0.11; NCP IP(1), y 5
0.22x 2 0.07; NCP IP(2), y 5 1.4x 2 0.84. ANCOVA dem-
onstrated that the slope of the regression lines for NC IP(1), HCP
IP(1) and NCP IP(1) groups, but not for others, are significantly
different from those for the NC IP(2) group, indicating that
IS-limiting effect observed in the NC group was abolished in the
HC group, restored in the HCP group and not affected in the
NCP group. Abbreviations as in Figure 1. Open circle 5 HC
IP(1); closed circle 5 HC IP(2); open triangle 5 HCP IP(1);
closed triangle 5 HCP IP(2); open square 5 NC IP(1); closed
square 5 NC IP(2); open diamond 5 NCP IP(1); closed
diamond 5 NCP IP(2).
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blunted activation of ecto-59-nucleotidase in this study may
be responsible for the blunted effect of IP in the HC rabbits,
and pravastatin may restore the effect of IP by restoring the
activation of ecto-59-nucleotidase. The mechanism of ecto-
59-nucleotidase activation by IP, which is blunted by HC
and restored by pravastatin, is left to be investigated.
Another possible mechanism left to be investigated is that,
since nitric oxide is reported to open the second window of
preconditioning (12–14), the depletion of nitric oxide by
HC (15) may attenuate cardioprotection, and pravastatin
may restore the IS-limiting effect of IP by upregulating (3)
the nitric oxide synthase. We do not have evidence to
support or negate this idea.
Clinical implications. Recently, increasing numbers of
studies have suggested the existence of IP in the clinical
settings. Preinfarction angina or prodrome has been re-
ported to be related to good left ventricular function after
MI in humans (2), and this may be due to the IS-limiting
effect of IP. Repeated reduction of coronary blood flow and
transient occlusion of coronary artery by the phenomenon of
cyclic flow variation is known to precede the permanent
thrombotic occlusion. Therefore, it is quite likely that
transient myocardial ischemia including the one without
chest pain (silent ischemia) precedes the onset of MI in
predominant numbers of patients, and this may induce IP.
Considering this evidence, our results suggest that HC
increases IS among the preconditioned patients, and this
attenuation of cardioprotection may be restored by treat-
ment with pravastatin.
Study limitations. Since there might be species differences,
our results with rabbits might not necessarily predict the
clinical outcome. Since we used a certain protocol for
developing IP, administering pravastatin or feeding choles-
terol, the results may be different if some different protocols
Figure 3. Cytosolic and ecto-59-nucleotidase activity of myocardium from the ischemic and nonischemic region immediately after the
procedure of ischemic preconditioning. Cytosolic and ecto-59-nucleotidase activities in the nonischemic region were increased by
hypercholesterolemia (HC and HCP groups) and pravastatin had no influence on them. However, the activation of ecto-59-nucleotidase
by ischemic preconditioning was blunted by hypercholesterolemia (HC group) and restored by pravastatin treatment (HCP group).
*Significantly different from NC group. HC 5 hypercholesterolemia; HCP 5 hypercholesterolemia treated with pravastatin, NC 5
normocholesterolemia.
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(multiple cycles of ischemia for IP, low dose of cholesterol
or acute administration of pravastatin) are used, which are
left to be tested. Since we revealed the effect of HC and
pravastatin on the IS-limiting effect of IP and on the
activation of ecto-59-nucleotidase activity separately, we can
not deny the possibility that these two phenomena are
coincidental. However, considering the results of the previ-
ous studies that IS correlates with the ecto-59-nucleotidase
activity of myocardium and its inhibition can abolish the
effect of IP, it may be probable that the changes in the IS are
determined by the changes in the ecto-59-nucleotidase
activation. Although we demonstrated the effects of prava-
statin, it is left to be determined whether the effects are
specific to this particular agent or are common among
HMG-CoA reductase inhibitors.
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